April 03, 2019
2 min read
Save

Heterogeneity seen with in vivo instrument-assisted patellofemoral evaluation methods

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Recently published results showed high heterogeneity within the in vivo instrument-assisted patellofemoral evaluation methods and measurement outcomes used to assess patellofemoral mobility, which demonstrated a need for better methodological standardization.

Perspective from James Bicos, , MD

Researchers performed a systematic review of PubMed, EMBASE, Cochrane Library and SPORTDiscuss electronic databases and identified 2,614 records of in vivo instrument-assisted patellofemoral evaluation of patellar mobility. A modified version of the Critical Appraisal Skills Program’s critical appraisal tool was used to assess the methodologic quality of the articles.

Of the 2,614 records, there were nine studies which included a total of 568 patients. Of these patients, 355 were asymptomatic; 87 had patellofemoral pain; and 126 patients had patellofemoral instability. Investigators noted the average maximum force applied to the patella by the instruments was 38.9 N.

The medial and lateral patellar displacement for asymptomatic patients ranged from 3.9 mm to 10.4 mm and 3.5 mm to 14.8 mm, respectively. Medial and lateral patellar displacement for patients with patellar instability ranged from 3.8 mm to 22.1 mm and 7 mm to 21.9 mm, respectively.

The patellar displacement mean values were similar for instability subgroups. Medial patellar displacement in patients with patellofemoral pain was 10 mm and was 10.9 mm for patients with pain and lateral displacement. Investigators noted that of 18 possible points, the mean methodological quality score was 9.8. – by Monica Jaramillo

Disclosures: The researchers report no relevant financial disclosures.